1. Home
  2. NUVL vs IDA Comparison

NUVL vs IDA Comparison

Compare NUVL & IDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$100.82

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Logo IDACORP Inc.

IDA

IDACORP Inc.

HOLD

Current Price

$144.26

Market Cap

6.9B

Sector

Utilities

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
IDA
Founded
2017
1915
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Electric Utilities: Central
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
8.0B
6.9B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
NUVL
IDA
Price
$100.82
$144.26
Analyst Decision
Strong Buy
Buy
Analyst Count
15
8
Target Price
$135.00
$135.25
AVG Volume (30 Days)
497.6K
500.1K
Earning Date
02-27-2026
02-19-2026
Dividend Yield
N/A
2.49%
EPS Growth
N/A
7.17
EPS
N/A
5.84
Revenue
N/A
$1,805,885,000.00
Revenue This Year
N/A
$7.90
Revenue Next Year
N/A
$8.27
P/E Ratio
N/A
$24.21
Revenue Growth
N/A
N/A
52 Week Low
$55.54
$108.15
52 Week High
$113.02
$142.06

Technical Indicators

Market Signals
Indicator
NUVL
IDA
Relative Strength Index (RSI) 49.64 77.24
Support Level $98.65 $134.31
Resistance Level $106.57 $137.28
Average True Range (ATR) 4.46 2.51
MACD -0.29 0.77
Stochastic Oscillator 47.36 94.40

Price Performance

Historical Comparison
NUVL
IDA

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About IDA IDACORP Inc.

Idacorp Inc is a holding company that, through its subsidiaries, acts as an electric utility engaged in the generation, transmission, distribution, sale, and purchase of electric energy and capacity. The companys only reportable segment is utility operations. The utility operations segment's primary source of revenue is the regulated operations of Idaho Power. The company serves commercial and industrial customers, which involved in food processing, electronics and general manufacturing, agriculture, health care, government, and education.

Share on Social Networks: